SyntekaBio

SyntekaBio Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 61.28 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 145.69 % — a change of -57.94% (lower).

Cash Conversion

61.28 %

YoY

-57.94%

Last updated:

Cash Conversion Rate (OCF/Net Income) of SyntekaBio is 2025 61.28 % . Cash Conversion Rate (OCF/Net Income) of SyntekaBio was 2024 145.69 % . It decreases by -57.94% lower compared to the previous year.

The SyntekaBio Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
-63.15 KRW
Jan 1, 2019
14.28 KRW
Jan 1, 2020
71.95 KRW
Jan 1, 2021
40.81 KRW
Jan 1, 2022
188.86 KRW
Jan 1, 2023
70.87 KRW
Jan 1, 2024
145.69 KRW
Jan 1, 2025
61.28 KRW
The SyntekaBio Cash Conversion history
YEARCash ConversionYoY
61.28 %-57.94%
145.69 %+105.56%
70.87 %-62.47%
188.86 %+362.82%
40.81 %-43.29%
71.95 %+403.70%
14.28 %-122.62%
-63.15 %-246.83%
43.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Cash Conversion Rate (OCF/Net Income) of SyntekaBio is 61.28 % in 2025.

Cash Conversion Rate (OCF/Net Income) of SyntekaBio changed from 145.69 % to 61.28 %, representing a -57.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s SyntekaBio with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SyntekaBio

All Key Metrics — SyntekaBio